Ependymoblastoma
MONDO:0016715Ependymoblastoma is a rare type of primitive neuroectodermal tumor (PNET) that usually occurs in young children under the age of 2 and is histologically distinguished by the production of ependymoblastic rosettes. It is associated with an aggressive course and a poor prognosis.
Also known as: ETMR, C19MC-altered, embryonal tumor with Multilayered Rosettes, embryonal tumor with Multilayered Rosettes with C19MC amplification, embryonal tumor with Multilayered Rosettes, C19MC-altered, embryonal tumor with abundant neuropil and true Rosettes, embryonal tumour with Multilayered Rosettes, embryonal tumour with Multilayered Rosettes with C19MC amplification, embryonal tumour with Multilayered Rosettes, C19MC-altered
2773 clinical trials for this condition and its sub-types, 5 tagged with Ependymoblastoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Ependymoblastoma
-
Pediatric cerebral ependymoblastoma 0 trials
-
Killer virus turned against childhood brain cancer
Disease control Recruiting nowThis early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for toddlers with aggressive brain cancer: experimental spinal-fluid chemo
Disease control Recruiting nowThis early-phase study tests whether adding chemotherapy directly into the spinal fluid (intrathecal topotecan) followed by maintenance pills is feasible for children under 6 with high-risk embryonal brain tumors. About 15 children will receive this treatment after standard high-…
Early phase 1 • Sponsor: C17 Council • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Experimental drug DFMO offered to kids with rare cancers
Disease control Expanded accessThis expanded access program provides the drug DFMO to children and young adults up to age 30 with rare relapsed tumors such as neuroblastoma or medulloblastoma. The goal is to control the disease by targeting specific genetic markers. Participants take DFMO by mouth twice daily,…
Sponsor: Giselle Sholler • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill shows promise in early brain tumor trial
Disease control Recruiting nowThis early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC